# Saros Therapeutics

Source: https://onco.cc/companies/saros-therapeutics/  
OnCo record `saros-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Saros Therapeutics is an Illinois company developing nanoparticles that carry immune-activating drugs to immune cells, to help the immune system attack tumours that checkpoint inhibitors do not reach.

## Summary

Saros Therapeutics describes a proprietary nanoparticle platform that targets innate immune cells for cancer and autoimmune disease, and is based at the Helix 51 incubator at Rosalind Franklin University of Medicine and Science in North Chicago (NIH RePORTER lists Chicago). In fiscal year 2026 NCI awarded it USD 1,164,203 under SBIR grant 1R44CA306545-01A1; the abstract describes nanoparticles that combine manganese with a STING agonist to strengthen STING activation, extend the agonist's half-life and target dendritic cells and macrophages, for intravenous use alongside checkpoint inhibitors in tumours that exclude T cells.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Saros Therapeutics Inc
- HQ: North Chicago, IL
- Type: biotech
- Website: https://sarostx.com/

## Notes

- The website names no cancer type, programme or founding year; the STING and manganese detail is from the award abstract. Read on sarostx.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://sarostx.com/
- NIH RePORTER: award 1R44CA306545-01A1: https://reporter.nih.gov/project-details/11410154

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/), [STING & innate immune agonists](https://onco.cc/technologies/sting-agonist/)

---
JSON: https://onco.cc/api/v1/entities/saros-therapeutics.json